Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics

Summary

Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing "multi-omics" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes. The aim is to comprehensively elucidate the pathogenesis and metabolic pathways of cachexia, thereby precisely identifying potential therapeutic targets capable of reversing this pathological process.

Eligibility

Inclusion Criteria:

* Age ≥ 18 years
* Signed informed consent form and voluntary participation in this study
* Histologically and/or cytologically confirmed diagnosis of cancer
* Patients with gastrointestinal malignancies, including:
* Esophageal cancer
* Hepatocellular carcinoma
* Gastric cancer
* Cholangiocarcinoma
* Patients undergoing histopathological examination of primary lesion biopsy or gastrointestinal endoscopic biopsy

Exclusion Criteria:

* Pregnant or lactating women
* Presence of contraindications to surgery
* Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability/unwillingness to cooperate
* Presence of two or more concurrent primary tumors

Conditions3

Browse More Trials